2015
DOI: 10.1016/j.jval.2015.09.145
|View full text |Cite
|
Sign up to set email alerts
|

Access to Innovative Drugs in Patients with Metastatic Lung Cancer in French Public Hospitals (the Territoire Study)

Abstract: We identified 11,602 patients receiving chemotherapy in public hospitals. During follow-up, 7,417 patients (63.9%) received expensive drugs at least once, including mostly pemetrexed (57.5%), bevacizumab (16.9%), or topotecan (7.2%); these patients were significantly more likely women and younger than the rest of the cohort (p< 0.0001). Conversely, all selected comorbidities were associated with lower rates of administration i.e. chronic renal failure, diabetes, hypertension, COPD and other respiratory disease… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
1

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
0
1
Order By: Relevance
“…Indeed, the model did not take into consideration certain potential confounding variables such as comorbidities and time since diagnosis. With this respect, our results differ from the results of the TERRITOIRE study, which has evaluated access of patients with lung cancer to expensive drugs in France as a function of geographical and socio-demographic factors, and which demonstrated some lack of social equity in access to expensive drugs [ 13 ]. The differences between our results and those of the TERRITOIRE study may be explained by the fact that we used a different version of the deprivation index; that the impact of social equity in using expensive drugs might vary according to the type of disease and other confounding variables such as comorbidities.…”
Section: Discussioncontrasting
confidence: 99%
“…Indeed, the model did not take into consideration certain potential confounding variables such as comorbidities and time since diagnosis. With this respect, our results differ from the results of the TERRITOIRE study, which has evaluated access of patients with lung cancer to expensive drugs in France as a function of geographical and socio-demographic factors, and which demonstrated some lack of social equity in access to expensive drugs [ 13 ]. The differences between our results and those of the TERRITOIRE study may be explained by the fact that we used a different version of the deprivation index; that the impact of social equity in using expensive drugs might vary according to the type of disease and other confounding variables such as comorbidities.…”
Section: Discussioncontrasting
confidence: 99%